Baxter’s BioScience business is a leader in recombinant and plasma-based protein replacement therapies to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products and developmental technology used in adult stem-cell therapies; and vaccines.
BioScience core franchises include: Hemophilia, Biotherapeutics, BioSurgery and Vaccines. BioScience products represent approximately 45 percent of Baxter’s annual sales, totaling $5.7 billion in 2010.
BioScience is a fully integrated business and includes discovery, development, manufacturing and operations, and commercial businesses in the areas of coagulation therapies, immune globulins for immune disorders, treatment for alpha 1-antitrypsin deficiency, vaccines and therapies for wound healing and treatments for shock.
Baxter is a leading manufacturer of antihemophilic clotting factor to treat hemophilia. This includes recombinant and plasma-based factor VIII – the clotting factor missing from the blood of people with hemophilia A – and a therapy called FEIBA [Anti-Inhibitor Coagulation Complex] for people that develop inhibitors against clotting factor. In 1992, the company introduced the first recombinant, or genetically manufactured, factor VIII known as Recombinate [Antihemophilic factor (Recombinant)], and improved the therapy in 2003 with the launch of ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method], the first recombinant factor VIII produced without any blood additives.
Baxter produces antibody-replacement therapy, or immune globulin intravenous (IVIG), to bolster the immune systems of people with immune-system disorders. IVIG is also being investigated as a possible treatment for other indications, including Alzheimer’s disease and certain neurological conditions.
Albumin is a plasma-volume expander used to treat burns and shock, and to maintain adequate fluid volume and pressure in critically ill patients. Baxter is the first and only company to offer albumin in a flexible, plastic container.
People with alpha 1-antitrypsin (AAT) deficiency have reduced levels of a blood protein that protects the lungs. The condition can result in early onset emphysema and premature death. Baxter’s plasma-based therapies raise the level of AAT in the blood.
Baxter's biosurgery products are biologically active products and are used to facilitate hemostasis and tissue sealing. The company's fibrin sealants, for example, are made up of human fibrinogen and human thrombin, which, when mixed, replicate the start of the tissue repair process to stop bleeding in certain surgical procedures.
Baxter’s vaccine development portfolio includes CELVAPAN and PREFLUCEL, the company’s candidate avian (H5N1) and seasonal influenza vaccines, and development work with Ross River and SARS. The influenza vaccines are produced using the company’s unique Vero-cell technology. This technology can produce a vaccine in about half of the time compared to traditional, egg-based production methods.
Baxter also produces leading vaccines for prevention of meningitis C, a highly infectious disease characterized by rapid onset of life-threatening and debilitating symptoms, and tick-borne encephalitis, a potentially fatal disease common in Europe.